Atopic Dermatitis

Alphyn Biologics’ study of AB-101a also evaluates patients who suffer from bacterial infections associated with atopic dermatitis.

In this episode, Jeffrey M. Cohen, MD, a board-certified medical dermatologist and the director of the Psoriasis Treatment Program at the Yale School of Medicine, discusses treatment options for adolescents with atopic dermatitis, how the changing seasons can affect flare-ups, and what caregivers can do at home to help prevent extreme itching.

A new study shows the AD drug does not interfere with vaccinations or increase severity.

In this week’s Pointers with Dr Portela, the 208SkinDoc discusses holistic medicine vs. western medicine for eczema treatment.

A real-world study of children with moderate-to-severe atopic dermatitis (AD) in China found Dupixent can reduce symptoms and improve pruritus. Traditional therapies had little effect, according to the researchers.

Recent study results demonstrated a noticeable reduction in itch just 12 hours after application of ruxolitinib.

The CHMP's recommendations are based on data from a phase 3 ECZTRA 6 trial in adolescents with moderate-to-severe AD cases.

A national study in Germany identified the baseline characteristics of patients with moderate-to-severe atopic dermatitis (AD) to understand how they are usually treated with Dupixent in the real world.

Dermatology experts discuss atopic dermatitis treatment in skin of color patients in this DermView series recap.

Joshua Zeichner, MD; Brittany Craiglow, MD; Elizabeth Swanson, MD; Vikash Oza, MD; and Raj Chovatiya, MD, PhD, provide take-home messages for dermatologists treating pediatric patients with atopic dermatitis.

Atopic dermatitis specialists discuss how to have a conversation with parents about risks of biologics and how to answer questions about length of therapy.

Expert pediatric dermatologists provide impressions on the case of a 12-year-old girl with atopic dermatitis.

Joshua Zeichner, MD, reviews the case of a 12-year-old girl with atopic dermatitis.

A new allergen, acetophenone azine with generalized autoeczematization, is the cause of “shin guard dermatitis.”

New sticky tape study can help predict onset of pediatric atopic eczema in babies.

Expert pediatric dermatologists discuss the importance of combination therapy and shared decision-making when treating pediatric patients with atopic dermatitis.

Brittany Craiglow, MD, and Joshua Zeichner, MD, discuss treatment adherence in pediatric patients with atopic dermatitis.

Vikash Oza, MD, provides clinical insight for Case 2, a 7-year-old female patient with atopic dermatitis.

Joshua Zeichner, MD; Brittany Craiglow, MD; Elizabeth Swanson, MD; and Vikash Oza, MD, address techniques for injectables when treating pediatric patients with atopic dermatitis.

Dr Joshua Zeichner reviews the case of a 7-year-old female patient with atopic dermatitis.

Joshua Zeichner, MD; Brittany Craiglow, MD; Elizabeth Swanson, MD; Vikash Oza, MD; and Raj Chovatiya, MD, PhD, discuss treatments beyond topical agents and the use of dupilumab in pediatric patients with atopic dermatitis.

Expert pediatric dermatologists Drs Elizabeth Swanson, Joshua Zeichner, and Raj Chovatiya share impressions from patient case No. 1.

Dr Joshua Zeichner reviews the case of a 2-year-old patient with atopic dermatitis.

INTEGUMENT-1 and 2 trial data for atopic dermatitis are expected at the end of 2022.

Drs Angela Lamb, Omar Noor, and Neal Bhatia share what they consider to be the biggest gaps in care for patients with SOC: patient/provider education, building trust, and appropriate diagnosis of AD.